Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options
Rositsa Koleva‐Kolarova, James Buchanan, Heleen Vellekoop, et al.
Applied Health Economics and Health Policy (2022) Vol. 20, Iss. 4, pp. 501-524
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe
Arnaud Bayle, Julia Bonastre, Dan Chaltiel, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 934-945
Closed Access | Times Cited: 59
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
Cambridge Prisms Precision Medicine (2024) Vol. 2
Open Access | Times Cited: 8
Alternative Payment Models for Innovative Medicines: A Framework for Effective Implementation
Frederick McElwee, Amanda Cole, Gomathi Kaliappan, et al.
Applied Health Economics and Health Policy (2025)
Open Access
Scaling nanopharmaceutical production for personalized medicine: challenges and strategies
Carolina de Souza Cardoso Delfino, Michelle Colão de Paula Pereira, Miguel Oliveira, et al.
Journal of Nanoparticle Research (2025) Vol. 27, Iss. 4
Closed Access
Precision public health perspective: Is genomic population screening a viable option for the early detection of risks for oncological diseases? Reflections from Serbia
Bosiljka Djikanović, Janko Janković, Milena Čavić
Srpski medicinski casopis Lekarske komore (2025) Vol. 6, Iss. 1, pp. 16-27
Open Access
Barriers and Facilitators to the Implementation of Personalised Medicine across Europe
Dorota Stefanicka-Wojtas, Donata Kurpas
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 203-203
Open Access | Times Cited: 10
Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
Sungkyung Lee, Jong Hyuk Lee
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 9
What is meant by ‘integrated personalized diabetes management’: A view into the future and what success should look like
Nick Guldemond
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S1, pp. 14-29
Open Access | Times Cited: 3
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)
Marcelien Callenbach, Daphne Schoenmakers, Rick A. Vreman, et al.
Value in Health (2024) Vol. 27, Iss. 8, pp. 1046-1057
Open Access | Times Cited: 3
A Systematic Review of Challenges and Opportunities in the Implementation of Managed Entry Agreements for Advanced Therapy Medicinal Products
Andrea Greco, Geert Frederix, Lotty Hooft, et al.
Clinical Therapeutics (2024)
Open Access | Times Cited: 3
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
Rositsa Koleva‐Kolarova, László Szilberhorn, Tamás Zelei, et al.
Personalized Medicine (2023) Vol. 20, Iss. 4, pp. 305-319
Open Access | Times Cited: 9
Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape
Костадин Костадинов, Yuliyana Marinova, Kostadin Dimitrov, et al.
Healthcare (2024) Vol. 12, Iss. 4, pp. 458-458
Open Access | Times Cited: 2
Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification
Vittoria Ardito, Oriana Ciani, Michael Drummond
PharmacoEconomics (2024)
Open Access | Times Cited: 2
Education for the translation of Advanced Therapy Medicinal Products
A. C. Davide, Eustachio Attico, Graziella Pellegrini
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital
Morten Ladekarl, Anne Krogh Nøhr, Mads Sønderkær, et al.
Acta Oncologica (2023) Vol. 62, Iss. 3, pp. 261-271
Open Access | Times Cited: 5
A survey of experts on personalized medicine landscape in European Union and China
Ilda Hoxhaj, Flavia Beccia, Alisha Morsella, et al.
BMC Health Services Research (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
An evaluation of managed access agreements in England based on stakeholder experience
Caroline Farmer, Maxwell S. Barnish, Laura A. Trigg, et al.
International Journal of Technology Assessment in Health Care (2023) Vol. 39, Iss. 1
Open Access | Times Cited: 4
Budget Impact and Transferability of Cost–effectiveness of DPYD Testing in Metastatic Breast Cancer in Three Health Systems
Rositsa Koleva‐Kolarova, Heleen Vellekoop, Simone Huygens, et al.
Personalized Medicine (2023) Vol. 20, Iss. 4, pp. 357-374
Closed Access | Times Cited: 4
Inborn errors of immunity: A field without frontiers
Giorgia Bucciol, Selket Delafontaine, Isabelle Meyts, et al.
Immunological Reviews (2023) Vol. 322, Iss. 1, pp. 15-27
Open Access | Times Cited: 4
On the modern evolution of personalized medicine
Edward Abrahams, Gregory J. Downing
Elsevier eBooks (2024), pp. 1-25
Closed Access | Times Cited: 1
Challenges for gene therapy in the financial sustainability of health systems: a scoping review
Hugo Ossandon, Nicolás Armijo, Constanza Vargas, et al.
Orphanet Journal of Rare Diseases (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 1
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
Marcelien Callenbach, Rick A. Vreman, Christine Leopold, et al.
PharmacoEconomics (2024)
Open Access | Times Cited: 1
The Evolving Landscape of Potency Assays
Jorge S. Burns
Advances in experimental medicine and biology (2023), pp. 165-189
Closed Access | Times Cited: 3
HEcoPerMed, Personalized Medicine from a Health Economic Perspective: Lessons Learned and Potential Opportunities Ahead
Maureen Rutten‐van Mölken, Matthijs Versteegh, Balázs Nagy, et al.
Personalized Medicine (2023) Vol. 20, Iss. 4, pp. 299-303
Open Access | Times Cited: 3
Early access schemes for innovative health technologies: the views of international stakeholders
Caroline Farmer, Brian I. O’Toole, Maxwell S. Barnish, et al.
International Journal of Technology Assessment in Health Care (2023) Vol. 39, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top